Axolotl Biologix and Carmell Therapeutics enter merger deal

13 Sep 2023
·
Deals
www.pharmaceutical-technology.com
Acquisition
Axolotl Biologix and Carmell Therapeutics enter merger deal
Preview
Source: Pharmaceutical Technology
With the deal closing, Axolotl will now function as a completely owned Carmell subsidiary. Credit: metamorworks/Shutterstock.com.
Moonshot incubator client Axolotl Biologix has finalised a merger with Carmell Therapeutics to bolster the regenerative medicine sector.
The merger will combine the expertise of Axolotl Biologix in regenerative therapies with Carmell’s capabilities in utilising the innate healing properties of the body.
Recommended Reports
Axolotl Biologix and Carmell Therapeutics enter merger deal
Preview
Source: Pharmaceutical Technology
ReportsMergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry - Implic... GlobalData
Axolotl Biologix and Carmell Therapeutics enter merger deal
Preview
Source: Pharmaceutical Technology
ReportsGlobal Mergers and Acquisitions (M&A) Deals in Pharma 2021 - Thematic Research GlobalData
View allCompanies IntelligenceCarmell CorpAxolotl Biologix IncView all
Axolotl Biologix focuses on progressing regenerative medicines to design and develop human amnion-based allograft products for soft tissue repair, as well as aesthetic and orthopaedic applications.
As per the deal terms, shareholders of Axolotl will receive an initial equity price of $65m, comprising $8m in cash and $57m in Carmell stock on the closing of the transaction.
Axolotl shareholders are also entitled to receive milestone equity payments of up to $75m in the future.
The milestone payments are contingent on meeting specified revenue and business targets and will comprise 12% in cash and 88% in Carmell stock.
With the deal closing, Axolotl will now function as a completely owned Carmell subsidiary.
Moonshot president and CEO Scott Hathcock said: “The merger between Carmell Therapeutics and Axolotl Biologix exemplifies the type of innovation and growth that Moonshot is designed to cultivate.
“This merger with an industry giant like Carmell Therapeutics is a significant development for the future of regenerative medicine.”
The combined business will also possess the scientific proficiency of Carmell and Axolotl’s practical developments.
A regenerative medicine platform company, Carmell develops allogeneic plasma-based biomaterials to enhance innate regenerative pathways for various bone and soft tissue indications.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.